In the world of whole-genome sequencing, do we really need cytogenetics anymore? To answer this question, Chadi brings on two cytogeneticists: Linda Baughn, PhD, and Yassmine Akkari, PhD. They begin by describing their unique career paths to becoming cytogeneticists, their day-to-day responsibilities, and what tests they perform and on what specimens. They then simplify the commonly used assays in their labs, how cytogenetic techniques are evolving (rather than dying), what whole genome sequencing looks like in the future, and topics that cytogeneticists disagree on, among other discussion points.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
